Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Varsha Gandhi, PhD, on Ibrutinib

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Sep

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

MD Anderson President Announces Retirement, Shares Leadership Transition Plans

ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment

Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma

Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer

High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT